AsemconnectVietnam - 2024 marks the 9th consecutive year that Bidiphar (DBD) pharmaceuticals has been included in the ranking of the most prestigious pharmaceutical companies in Vietnam with the position of Top 4, up 1 place compared to 2023.

The ranking is based on three main criteria, including Financial capacity (based on the most recent financial statements); Media reputation - assessed through the Media Coding method, encoding articles related to the company on reputable media; and conducting a survey of related subjects, including customers, partners and experts in the industry, conducted in October-November 2024.
This success reflects the company's efforts in product development, market expansion and affirming its position in the medical and healthcare industry.
DBD possesses strong competitiveness with a very attractive product portfolio, including antibiotics, cancer treatment drugs and dialysis solutions, which are the 3 main treatment groups of DBD, contributing about 65% of total revenue and 51% of the company's gross profit in the first 9 months of 2024.
For anti-cancer drugs, DBD is the domestic pharmaceutical enterprise with the highest market share in the ETC channel drug bidding structure. For dialysis solutions, DBD is currently ranked 3rd out of 5 enterprises with the ability to supply in the ETC channel. DBD is assessed to have a lot of room for long-term growth for DBD's anti-cancer drugs and dialysis solutions.
The basis for this assessment is based on the prospect of increasing drug demand when these diseases are a huge burden for Vietnamese people. In addition, upgrading the production line to EU-GMP standards, investing in the construction of 2 new factories and policies to ease bidding regulations at the hospital channel of the Government, DBD can participate in bidding for drugs in the ETC channel in groups 1 and 2 from 2026, supporting the strategy of expanding domestic market share through the ETC channel.
DBD's advantage also lies in its more competitive product prices compared to imported products. In July, DBD also cooperated with Crearene AG - Switzerland to affirm DBD's leading position in the field of dialysis treatment in Vietnam.
N.Nga
Source: VITIC/Tinnhanhchungkhoan